On July 16, 2024, S&P Global hosted the “Seizing Opportunity, Driving a Sustainable Future—S&P Global Sustainable1 Seminar and Sustainability Yearbook (China Edition) 2024 Launch Ceremony” in Beijing. Imeik Technology Development Co., Ltd. (Imeik) was officially included in the Sustainability Yearbook (China Edition) 2024, in recognition of its long-term commitment to environmental, social and governance (ESG) performance. Among the only two biotechnology firms featured this year, Imeik was the sole recipient of the "Industry Mover" distinction.
S&P Global’s Corporate Sustainability Assessment (CSA) is one of the world’s largest and most authoritative ESG evaluation frameworks, measuring companies’ sustainability performance across economic, environmental, and social dimensions from an investment perspective. This year marks the 20th anniversary of the global Sustainability Yearbook and the second year of publishing its China edition, which focuses exclusively on Chinese enterprises. The Yearbook identifies and honours companies demonstrating industry-leading sustainable development capabilities, based on transparent, rigorous, and impartial CSA results.
For the 2024 edition, S&P Global assessed more than 1,700 Chinese companies across over 60 industries. After applying defined exclusion criteria, approximately 120 companies with the highest CSA scores and best overall performance were selected. To qualify, a company’s CSA score must place it in the top 15% of its industry and be within 30% of the highest industry score.
Imeik’s sustained efforts in responsible operations, environmental protection, and transparent ESG disclosures have set a benchmark within the biotech sector and earned it international recognition. From 2022 to 2023, Imeik significantly improved its CSA score, outpacing industry peers. As of July 2024, the company ranks above 96% of global biotech companies. In recognition of this advancement, S&P Global awarded Imeik the "Industry Mover" badge—an accolade reserved for companies in the top 15% of their sector that achieved the highest year-on-year score improvement of at least 5%.
This distinction not only affirms Imeik’s past achievements, but also signals strong confidence in its long-term potential for sustainable growth.
Since its founding, Imeik has remained committed to its mission: "to bring greater quality and dignity to life," and its ethos of "enabling beauty through technology." The company believes in aligning business success with societal progress, aspiring to help individuals embrace health, cultivate emotional connections, and pursue vibrant, hopeful lives.
Imeik has built a three-tier ESG management structure involving its Board of Directors, senior executives, departments, and subsidiaries. It has embedded sustainability into its business operations, continuously refining its strategic pillars and ESG priorities to build a more comprehensive and efficient sustainability framework.
As an innovative biotech company, Imeik actively aligns with national strategies, promotes scientific innovation, attracts research talent, and places strong emphasis on intellectual property protection. The company also implements China’s dual carbon goals, safeguards employee rights, and strengthens data security. By working closely with stakeholders, Imeik strives to maximise economic, environmental, and social value—paving the way for a multi-win model of sustainable development.
Steadfast in its purpose, undeterred in its journey—Imeik remains committed to advancing sustainability through deeper investment and practice. The company will continue to take tangible action, fulfilling its corporate responsibility and contributing its strength to building a healthier, more beautiful China and a better life for all.
